Reference | Study design | Duration | Population | Osteoporosis treatments | Methodology | Results |
Eliasaf et al 24 | Observational prospective study | 6-month period | Postmenopausal women (n=86) | Oral BPS (n=39) Intravenous ZOL annually (n=12) Other therapies (n=35) | Question about their preferences regarding the frequency of the dosing regimen | •57% preferred annual treatment •22% preferred monthly treatment over other possibilities such as daily, weekly or every 6 months •5% preferred to receive treatment every 6 months |
Hadji et al 29 | Randomised controlled trial | 12-month period | Postmenopausal women (n=604) (408 ZOL) (196 ALE) | Intravenous ZOL annually (n=408) Oral ALE weekly (n=196) | (1)Remain on same therapy or change?: Remain/change/missing (2) Easy to manage medication: Not at all/somewhat/very/extremely/missing (3) Medication fits with lifestyle: Not at all/somewhat/very/extremely/missing (4) Convenient to take medication: Not at all/somewhat/very/extremely/missing (5) Willing to continue to use medication: Not at all/somewhat/very/extremely/missing (6) Most important reason for preference: Too medicines/not effective/experienced side effects/intake too inconvenient/did not like infusion/forgot to take it/did not like taking pills regularly/other | ZOL group: •80.9% preferred to continue with intravenous treatment. ALE group: •48.7% preferred to continue with oral administration. •42.9% (82/191) preferred to switch to the alternative treatment of a once-yearly infusion |
Orwoll et al 32 | Randomised controlled trial | 12-month period | Men with osteoporosis (n=302) | Intravenous ZOL annually+oral placebo weekly (n=154) Oral ALE weekly+intravenous placebo annually (n=148) | Which regimen was: (1) More convenient (2) More satisfying (3) More appealing to be taken for a longer period (4) Preferred | •74.2% preferred once-yearly intravenous infusion. •15.3% preferred weekly oral ALE. •10.5% had no preference |
Ryzner et al 33 | Prospective telephone survey | 24-month period | Osteoporosis clinic staffed by a rheumatologist and clinical pharmacists | None (n=56) Weekly oral (n=28) Monthly oral (n=2) Injection every 3 months (n=4) Yearly injection (n=0)* | Set of questions to determinate the route and frequency of BPS administration that the patients: (1) Prefer (2) Is most convenient (3) Is easiest to remember | •24.4% preferred once-monthly or once-yearly regimens •53.3% indicated preference for schedules that were once-monthly or less frequent •33.3% indicated that once-yearly infusion was the most convenient |
Reid et al 31 | Randomised controlled trial | 12-month period | Patients with ZOL or RIS for prevention and treatment of GIO (n=833) | Intravenous ZOL annually+oral placebo daily (n=416) Oral RIS daily+a single infusion of intravenous placebo (n=417) | Not specified | •81% preferred the intravenous preparation and 9% the oral preparation for convenience •78% preferred the intravenous preparation and 8% the oral preparation for satisfaction •84% were willing to take the intravenous preparation long term and 9% the oral preparation |
McClung et al 27 | Randomised controlled trial | 12-month period | Postmenopausal women who were receiving oral ALE for at least 1 year immediately prior to randomisation (n=225) | Intravenous ZOL+oral placebo weekly (n=113) Oral ALE weekly+a single infusion of intravenous placebo (n=112) | Which treatment regimen they thought: (1) Was more convenient (2) Better fit their lifestyle (3) They would be more willing to take for a long period of time (multiple years) (4) They preferred. | •78.7% preferred once-yearly intravenous infusion •9% preferred once-a-week capsules •11.8% considered equal both treatments |
Saag et al 28 | Randomised controlled trial | 24-month period | Postmenopausal women (n=128) | Intravenous ZOL+oral placebo weekly (n=69) Oral ALE weekly+a single infusion of intravenous placebo (n=59) | Which treatment: (1) They considered more convenient (2) They considered more satisfying (3) They would be willing to take for a long period of time (4) They preferred | •66.4% preferred once-yearly intravenous infusion •19.7% preferred weekly oral ALE •13.9% had no preference |
Fraenkel et al 30 | Observational Prospective study | Non-described | Postmenopausal women and men (n=212) | Oral BPS weekly Intravenous BPS quarterly Intravenous BPS yearly | After of an educational session participants completed an ACA questionnaire to determine their treatment preferences for: (1) Oral BPS taken once per week (2) Intravenous BPS given every 3 months (3) Intravenous BPS given once per year | •44.3% preferred once-yearly intravenous infusion •40.1% preferred weekly oral •2.8% preferred quarterly intravenous infusion •10.4% undecided |
*Yearly injectable bisphosphonate therapy had not yet been approved by the Food and Drug Administration at the time of study initiation.
ACA, adaptive conjoint analysis; ALE, alendronate; BPS , bisphosphonates; GIO, glucocorticoid-induced osteoporosis; RIS, risedronate; ZOL, zoledronic acid.